A pathogenic hallmark of rheumatoid arthritis (RA) is persistent activation of self-reactive CD4+ T cells. The cause of this aberrant activity remains elusive. We report here detection of autoantibodies against B7-H1, a recently described member of the B7 family, in 29% of patients with RA versus 4% of healthy donors. High-level expression of cell surface B7-H1 are found on activated human CD4+, CD8+, and CD45RO+ T cells. Immobilized autoantibodies to B7-H1 are capable of costimulating the proliferation of CD4+ T cells in vitro, and the presence of these autoantibodies correlates with active disease status. Using immobilized B7-H1 mAb’s and programmed death 1Ig, we demonstrate that engagement of B7-H1 on CD4+ T cells costimulates proliferation and secretion of IL-10, and subsequently leads to programmed cell death, accompanied with upregulated expression of TNF-related apoptosis–inducing ligand and activation of caspase-3. Taken together with our previous findings, these data indicate a bidirectional signaling role of B7-H1 in T cell costimulation and apoptosis and implicate B7-H1 autoantibodies as contributing to the progression of RA by inducing aberrant T cell responses.
Haidong Dong, Scott E. Strome, Eric L. Matteson, Kevin G. Moder, Dallas B. Flies, Gefeng Zhu, Hideto Tamura, Colin L.W. Driscoll, Lieping Chen
Title and authors | Publication | Year |
---|---|---|
Exploring the Complexity and Promise of Tumor Immunotherapy in Drug Development
Feng Y, He C, Liu C, Shao B, Wang D, Wu P |
International journal of molecular sciences | 2024 |
Exploring the gut microbiome: probiotics, prebiotics, synbiotics, and postbiotics as key players in human health and disease improvement
Kim YT, Mills DA |
Food Science and Biotechnology | 2024 |
Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
Long Y, Yu X, Chen R, Tong Y, Gong L |
Frontiers in immunology | 2022 |
CMTM6 as a master regulator of PD-L1.
Yaseen MM, Abuharfeil NM, Darmani H |
Cancer Immunology, Immunotherapy | 2022 |
Bridging the Gap: Connecting the Mechanisms of Immune-Related Adverse Events and Autoimmunity Through PD-1
Mor A, Strazza M |
Frontiers in Cell and Developmental Biology | 2022 |
Beyond Cancer: Regulation and Function of PD-L1 in Health and Immune-Related Diseases
Beenen AC, Sauerer T, Schaft N, Dörrie J |
International journal of molecular sciences | 2022 |
Plasma autoantibodies IgG and IgM to PD1/PDL1 as potential biomarkers and risk factors of lung cancer.
Li J, Liu M, Zhang X, Ji L, Yang T, Zhao Y, Wang Z, Liang F, Dai L |
Journal of Cancer Research and Clinical Oncology | 2022 |
Tumor microenvironment antigens.
Andersen MH |
Seminars in Immunopathology | 2022 |
Soluble immune checkpoint molecules in patients with antineutrophil cytoplasmic antibody-associated vasculitis.
Pyo JY, Yoon T, Ahn SS, Song JJ, Park YB, Lee SW |
Scientific Reports | 2022 |
PD-1/PD-L1 Axis as a Potential Therapeutic Target for Multiple Sclerosis: A T Cell Perspective
HX Li, C Zheng, J Han, J Zhu, S Liu, T Jin |
Frontiers in cellular neuroscience | 2021 |
The Role of Programmed Death-1 in Type 1 Diabetes
CG Tucker, AJ Dwyer, BT Fife, T Martinov |
Current Diabetes Reports | 2021 |
The PD-1:PD-L1 axis in Inflammatory Arthritis
M Canavan, A Floudas, DJ Veale, U Fearon |
BMC Rheumatology | 2021 |
The generation of PD-L1 and PD-L2 in cancer cells: From nuclear chromatin reorganization to extracellular presentation
Z Fan, C Wu, M Chen, Y Jiang, Y Wu, R Mao, Y Fan |
Acta pharmaceutica Sinica. B | 2021 |
Apoptosis, Autophagy, NETosis, Necroptosis, and Pyroptosis Mediated Programmed Cell Death as Targets for Innovative Therapy in Rheumatoid Arthritis
J Zhao, P Jiang, S Guo, S Schrodi, D He |
Frontiers in immunology | 2021 |
Single-cell transcriptome analysis of the heterogeneous effects of differential expression of tumor PD-L1 on responding TCR-T cells.
Ding R, Liu S, Wang S, Chen H, Wang F, Xu Q, Zhu L, Dong X, Gu Y, Zhang X, Chao CC, Gao Q |
Theranostics | 2021 |
Adipose-Tissue-Derived Mesenchymal Stem Cells Mediate PD-L1 Overexpression in the White Adipose Tissue of Obese Individuals, Resulting in T Cell Dysfunction.
Eljaafari A, Pestel J, Le Magueresse-Battistoni B, Chanon S, Watson J, Robert M, Disse E, Vidal H |
Cells | 2021 |
Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
Khalique H, Baugh R, Dyer A, Scott EM, Frost S, Larkin S, Lei-Rossmann J, Seymour LW |
Journal for ImmunoTherapy of Cancer | 2021 |
Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma.
Li L, Lu G, Liu Y, Gong L, Zheng X, Zheng H, Gu W, Yang L |
Frontiers in Oncology | 2021 |
Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy.
Tan Q, Dai L, Wang Y, Liu S, Liang T, Luo R, Wang S, Lou N, Chen H, Zhou Y, Zhong Q, Yang J, Xing P, Hu X, Liu Y, Zhou S, Yao J, Wu D, Zhang Z, Tang L, Yu X, Han X, Shi Y |
Cancer Immunology, Immunotherapy | 2021 |
Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human lung cancer and myeloma
Noffar Bar, Federica Costa, Rituparna Das, Alyssa Duffy, Mehmet K. Samur, Samuel S. McCachren, Scott Gettinger, Natalia Neparidze, Terri L. Parker, Jithendra Kini Bailur, Katherine E. Pendleton, Richa Bajpai, Lin Zhang, Mina L. Xu, Tara Anderson, Nicola Giuliani, Ajay K. Nooka, Hearn J. Cho, Aparna Raval, Mala Shanmugam, Kavita M. Dhodapkar, Madhav Dhodapkar |
JCI Insight | 2020 |
Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients
Q Tan, D Wang, J Yang, P Xing, S Yang, Y Li, Y Qin, X He, Y Liu, S Zhou, H Duan, T Liang, H Wang, Y Wang, S Jiang, F Zhao, Q Zhong, Y Zhou, S Wang, J Dai, J Yao, D Wu, Z Zhang, Y Sun, X Han, X Yu, Y Shi |
Theranostics | 2020 |
Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges
S Nimmagadda |
Cancers | 2020 |
Combination rhIL-15 and Anti-PD-L1 (Avelumab) Enhances HIVGag-Specific CD8 T-Cell Function
BA Goshu, H Chen, M Moussa, J Cheng, M Catalfamo |
The Journal of Infectious Diseases | 2020 |
PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer
B Diskin, S Adam, MF Cassini, G Sanchez, M Liria, B Aykut, C Buttar, E Li, B Sundberg, RD Salas, R Chen, J Wang, M Kim, MS Farooq, S Nguy, C Fedele, KH Tang, T Chen, W Wang, M Hundeyin, JA Rossi, E Kurz, MI Haq, J Karlen, E Kruger, Z Sekendiz, D Wu, SA Shadaloey, G Baptiste, G Werba, S Selvaraj, C Loomis, KK Wong, J Leinwand, G Miller |
Nature Immunology | 2020 |
Lung Cancer Survival in Patients With Autoimmune Disease.
Jacob S, Rahbari K, Tegtmeyer K, Zhao J, Tran S, Helenowski I, Zhang H, Walunas T, Varga J, Dematte J, Villaflor V |
2020 | |
The evolving role of immuno-oncology for the treatment of head and neck cancer: I-O and Head and Neck Cancer
AL Strome, X Zhang, SE Strome |
Laryngoscope Investigative Otolaryngology | 2019 |
Hepatic expression of programmed death-1 (PD-1) and its ligand, PD-L1, in children with autoimmune hepatitis: relation to treatment response
H Agina, N Ehsan, T Abd-Elaziz, G Abd-Elfatah, E Said, M Sira |
Clinical and Experimental Hepatology | 2019 |
Inflammation induced PD-L1-specific T cells
S Munir, MT Lundsager, MA Jørgensen, M Hansen, TH Petersen, CM Bonefeld, C Friese, Ö Met, P thor Straten, MH Andersen |
2019 | |
A Novel Anti-PD-L1 Vaccine for Cancer Immunotherapy and Immunoprevention
J Chen, H Liu, T Jehng, Y Li, Z Chen, KD Lee, HT Shen, L Jones, XF Huang, SY Chen |
Cancers | 2019 |
The T-win® technology: immune-modulating vaccines
MH Andersen |
Seminars in Immunopathology | 2018 |
Immune Checkpoints as Therapeutic Targets in Autoimmunity
C Paluch, AM Santos, C Anzilotti, RJ Cornall, SJ Davis |
Frontiers in immunology | 2018 |
Inhibitory Receptors and Pathways of Lymphocytes: The Role of PD-1 in Treg Development and Their Involvement in Autoimmunity Onset and Cancer Progression
E Gianchecchi, A Fierabracci |
Frontiers in immunology | 2018 |
Elevated serum autoantibodies against co-inhibitory PD-1 facilitate T cell proliferation and correlate with disease activity in new-onset systemic lupus erythematosus patients
H Shi, J Ye, J Teng, Y Yin, Q Hu, X Wu, H Liu, X Cheng, Y Su, M Liu, J Gu, T Lu, HJ Chen, H Zheng, Y Sun, C Yang |
Arthritis Research & Therapy | 2017 |
Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells
RM Johnson, H Dong |
Frontiers in immunology | 2017 |
Cancer Clonal Theory, Immune Escape, and Their Evolving Roles in Cancer Multi-Agent Therapeutics
JL Messerschmidt, P Bhattacharya, GL Messerschmidt |
Current Oncology Reports | 2017 |
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas
ZY Xu-Monette, J Zhou, KH Young |
Blood | 2017 |
Anti-regulatory T cells
MH Andersen |
Seminars in Immunopathology | 2016 |
A Cytokine-Independent Approach To Identify Antigen-Specific Human Germinal Center T Follicular Helper Cells and Rare Antigen-Specific CD4+ T Cells in Blood
JM Dan, CS Arlehamn, D Weiskopf, RS Antunes, C Havenar-Daughton, SM Reiss, M Brigger, M Bothwell, A Sette, S Crotty |
Journal of immunology (Baltimore, Md. : 1950) | 2016 |
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
W Zou, JD Wolchok, L Chen |
Science Translational Medicine | 2016 |
Co-stimulatory and Co-inhibitory Pathways in Autoimmunity
Q Zhang, DA Vignali |
Immunity | 2016 |
Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction
D Hendriks, Y He, I Koopmans, VR Wiersma, RJ van Ginkel, DF Samplonius, W Helfrich, E Bremer |
OncoImmunology | 2016 |
Soluble programmed cell death receptor-1 (sPD-1): a potential biomarker with anti-inflammatory properties in human and experimental acute respiratory distress syndrome (ARDS)
SF Monaghan, CS Chung, Y Chen, J Lomas-Neira, WG Fairbrother, DS Heffernan, WG Cioffi, A Ayala |
Journal of Translational Medicine | 2016 |
Programed death-1/programed death-ligand 1 expression in lymph nodes of HIV infected patients: results of a pilot safety study in rhesus macaques using anti–programed death-ligand 1 (Avelumab)
AL Gill, SA Green, S Abdullah, CL Saout, S Pittaluga, H Chen, R Turnier, J Lifson, S Godin, J Qin, MC Sneller, JM Cuillerot, H Sabzevari, HC Lane, M Catalfamo |
AIDS | 2016 |
B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8+ T cells
X Liu, X Wu, S Cao, SM Harrington, P Yin, AS Mansfield, H Dong |
Scientific Reports | 2016 |
Hepatic stellate cells: central modulators of hepatic carcinogenesis
AI Thompson, KP Conroy, NC Henderson |
BMC Gastroenterology | 2015 |
Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy
MH Andersen |
JNCI Journal of the National Cancer Institute | 2015 |
Comparison of biomarkers for systemic juvenile idiopathic arthritis
S Shenoi, JN Ou, C Ni, C Macaubas, VH Gersuk, CA Wallace, ED Mellins, AM Stevens |
Pediatric Research | 2015 |
Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies
Y Xia, LJ Medeiros, KH Young |
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer | 2015 |
Influence of PD-L1 cross-linking on cell death in PD-L1-expressing cell lines and bovine lymphocytes
R Ikebuchi, S Konnai, T Okagawa, K Yokoyama, C Nakajima, Y Suzuki, S Murata, K Ohashi |
Immunology | 2014 |
Targeting Apoptosis in Autoimmune Hepatitis
AJ Czaja |
Digestive Diseases and Sciences | 2014 |
Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality
A Saha, K Aoyama, PA Taylor, BH Koehn, RG Veenstra, A Panoskaltsis-Mortari, DH Munn, WJ Murphy, M Azuma, H Yagita, BT Fife, MH Sayegh, N Najafian, G Socie, R Ahmed, GJ Freeman, AH Sharpe, BR Blazar |
Blood | 2013 |
Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells
L Wang, J Qian, Y Lu, H Li, H Bao, D He, Z Liu, Y Zheng, J He, Y Li, S Neelapu, J Yang, LW Kwak, Q Yi, Z Cai |
Haematologica | 2013 |
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer
M Sznol, L Chen |
Clinical cancer research | 2013 |
PD-L1 is increased in the spinal cord and infiltrating lymphocytes in experimental allergic encephalomyelitis
M Li, J Jiang, B Fu, J Chen, Q Xue, W Dong, Y Gu, L Tang, L Xue, Q Fang, M Wang, X Zhang |
NEURAL REGEN RES | 2013 |
The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4 + T cells
S Munir, GH Andersen, IM Svane, MH Andersen |
OncoImmunology | 2013 |
Structure and Interactions of the Human Programmed Cell Death 1 Receptor
X Cheng, V Veverka, A Radhakrishnan, LC Waters, FW Muskett, SH Morgan, J Huo, C Yu, EJ Evans, AJ Leslie, M Griffiths, C Stubberfield, R Griffin, AJ Henry, A Jansson, JE Ladbury, S Ikemizu, MD Carr, SJ Davis |
The Journal of biological chemistry | 2013 |
Immunoregulatory molecules are master regulators of inflammation during the immune response
H la Fuente, D Cibrián, F Sánchez-Madrid |
FEBS Letters | 2012 |
B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma
D Hua, J Sun, Y Mao, LJ Chen, YY Wu, XG Zhang |
World journal of gastroenterology : WJG | 2012 |
Tubular cell HIV-entry through apoptosed CD4 T cells: A novel pathway
P Singh, H Goel, M Husain, X Lan, J Mikulak, A Malthotra, S Teichberg, H Schmidtmayerova, PC Singhal |
Virology | 2012 |
B7-h1 expressed by activated CD8 T cells is essential for their survival
V Pulko, KJ Harris, X Liu, RM Gibbons, SM Harrington, CJ Krco, ED Kwon, H Dong |
Journal of immunology (Baltimore, Md. : 1950) | 2011 |
B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance
JJ Park, R Omiya, Y Matsumura, Y Sakoda, A Kuramasu, MM Augustine, S Yao, F Tsushima, H Narazaki, S Anand, Y Liu, SE Strome, L Chen, K Tamada |
Blood | 2010 |
B7-H1 expression on old CD8+ T cells negatively regulates the activation of immune responses in aged animals
N Mirza, MA Duque, AL Dominguez, AG Schrum, H Dong, J Lustgarten |
Journal of immunology (Baltimore, Md. : 1950) | 2010 |
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd |
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology | 2009 |
Potential Role of Decoy B7-H4 in the Pathogenesis of Rheumatoid Arthritis: A Mouse Model Informed by Clinical Data
T Azuma, G Zhu, H Xu, AC Rietz, CG Drake, EL Matteson, L Chen, YJ Liu |
PLoS Medicine | 2009 |
The complex role of B7 molecules in tumor immunology
B Seliger, FM Marincola, S Ferrone, H Abken |
Trends in Molecular Medicine | 2008 |
Blockade of endogenous B7-H1 suppresses antibacterial protection after primary Listeria monocytogenes infection
SK Seo, HY Jeong, SG Park, SW Lee, IW Choi, L Chen, I Choi |
Immunology | 2008 |
TREM-2 mediated signaling induces antigen uptake and retention in mature myeloid dendritic cells.
Radhakrishnan S, Arneson LN, Upshaw JL, Howe CL, Felts SJ, Colonna M, Leibson PJ, Rodriguez M, Pease LR |
Journal of immunology (Baltimore, Md. : 1950) | 2008 |
PDL-1 blockade impedes T cell expansion and protective immunity primed by attenuated Listeria monocytogenes.
Rowe JH, Johanns TM, Ertelt JM, Way SS |
Journal of immunology (Baltimore, Md. : 1950) | 2008 |
PD-1 and Its Ligands in Tolerance and Immunity
Keir ME, Butte MJ, Freeman GJ, Sharpe AH |
Annual Review of Immunology | 2008 |
Polymorphisms of Genes for Programmed Cell Death 1 Ligands in Patients with Rheumatoid Arthritis
SC Wang, CH Lin, RN Li, TT Ou, CC Wu, WC Tsai, HW Liu, JH Yen |
Journal of Clinical Immunology | 2007 |
Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma
ZZ Yang, AJ Novak, MJ Stenson, TE Witzig, SM Ansell |
Blood | 2006 |
Advances in Immunology
AJ Korman, KS Peggs, JP Allison |
Advances in immunology | 2006 |
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.
Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G, Elkum N, Alshabanah M, Bin Amer S, Tulbah A, Ajarim D, Al-Tweigeri T, Dermime S |
Neoplasia (New York, N.Y.) | 2006 |
Costimulation-based immunotherapy for head and neck cancer
SE Strome, L Chen |
Current Treatment Options in Oncology | 2004 |
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
RH Thompson, MD Gillett, JC Cheville, CM Lohse, H Dong, WS Webster, KG Krejci, JR Lobo, S Sengupta, L Chen, H Zincke, ML Blute, SE Strome, BC Leibovich, ED Kwon |
Proceedings of the National Academy of Sciences | 2004 |
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells
YE Latchman, SC Liang, Y Wu, T Chernova, RA Sobel, M Klemm, VK Kuchroo, GJ Freeman, AH Sharpe |
Proceedings of the National Academy of Sciences | 2004 |
Interplay between IFN-gamma and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation
Rachel M. McLoughlin, Janusz Witowski, Rachel L. Robson, Thomas S. Wilkinson, Suzanne M. Hurst, Anwen S. Williams, John D. Williams, Stefan Rose-John, Simon A. Jones, Nicholas Topley |
Journal of Clinical Investigation | 2003 |
Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis
AD Salama, T Chitnis, J Imitola, MJ Ansari, H Akiba, F Tushima, M Azuma, H Yagita, MH Sayegh, SJ Khoury |
Journal of Experimental Medicine | 2003 |
Immunology of B7-H1 and Its Roles in Human Diseases
H Tamura, K Ogata, H Dong, L Chen |
International Journal of Hematology | 2003 |
B7-H1 pathway and its role in the evasion of tumor immunity
H Dong, L Chen |
Journal of Molecular Medicine | 2003 |